-
Swiatek wins in 58 minutes as Poland reach United Cup semis
-
Grok limits AI image editing to paid users after nudes backlash
-
Ski great Hirscher pulls out of Olympics, ends season
-
Kyiv mayor calls for temporary evacuation after Russian strikes
-
'War is back in vogue,' Pope Leo says
-
Storms pummel northern Europe causing travel mayhem and power cuts
-
France has right to say 'no' to US, Paris says
-
TikTok drives 'bizarre' rush to Prague library's book tower
-
EU countries override France to greenlight Mercosur trade deal
-
Russia joins Chinese, Iran warships for drills off S.Africa
-
Stocks rise ahead of US jobs data and key tariffs ruling
-
'All are in the streets': Iranians defiant as protests grow
-
Kurdish fighters refuse to leave Syria's Aleppo after truce
-
Grok turns off AI image generation for non-payers after nudes backlash
-
Germany factory output jumps but exports disappoint
-
Defiant Khamenei insists 'won't back down' in face of Iran protests
-
Russian strikes cut heat to Kyiv, mayor calls for temporary evacuation
-
Switzerland holds day of mourning after deadly New Year fire
-
Trump says US oil pledged $100 bn for Venezuela ahead of White House meeting
-
Hundreds of thousands without power as storms pummel Europe
-
Man City win race to sign forward Semenyo
-
Experts say oceans soaked up record heat levels in 2025
-
'Would be fun': Alcaraz, Sinner tease prospect of teaming up in doubles
-
Man City win race to sign Semenyo
-
Chinese AI unicorn MiniMax soars 109 percent in Hong Kong debut
-
Iran rocked by night of protests despite internet blackout: videos
-
Stocks mixed ahead of US jobs, Supreme Court ruling
-
Swiatek romps to United Cup victory in 58 minutes
-
Procession of Christ's icon draws thousands to streets of Philippine capital
-
Every second counts for Japan's 'King Kazu' at 58
-
Syria announces ceasefire with Kurdish fighters in Aleppo
-
Russia hits Ukraine with hypersonic missile after rejecting peacekeeping plan
-
Hundreds of thousands without power as Storm Goretti pummels Europe
-
Asian stocks mixed ahead of US jobs, Supreme Court ruling
-
Scores without power as Storm Goretti pummels Europe
-
Sabalenka gets revenge over Keys in repeat of Australian Open final
-
Fresh from China, South Korea president to visit Japan
-
Injured Kimmich to miss icy Bundesliga return for Bayern
-
Rybakina has little hope of change to tennis schedule
-
Osimhen, Nigeria seek harmony with Algeria up next at AFCON
-
US immigration agent's fatal shooting of woman leaves Minneapolis in shock
-
After fire tragedy, small Swiss town mourns 'decimated generation'
-
Switzerland mourns Crans-Montana fire tragedy
-
Russia bombards Kyiv after rejecting peacekeeping plan
-
Crunch time for EU's long-stalled Mercosur trade deal
-
Wawrinka gets Melbourne wildcard but Kyrgios to play doubles only
-
Asian stocks rally ahead of US jobs, Supreme Court ruling
-
'Sever the chain': scam tycoons in China's crosshairs
-
Bulls-Heat NBA game postponed over 'moisture' on court
-
Arsenal's Martinelli 'deeply sorry' for shoving injured Bradley
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
H.Darwish--SF-PST